not sure why gender and masculinity is even relevant here. No question about Rebecca's credentials - PHD in cell therapy and former executive at Novartis. furthermore, she is making great strides to progress our clinical trials in the US and AU with a small team.
cash burn has been contained, funding position is looking better. Importantly, Rebecca was the one that secured the $4m non dilutionary funding (Paul Hopper had nothing to do with it).
And now the early data from CDH17 (lowest dose level) is looking great!
CHM Price at posting:
0.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)